Digital Support for Cutting Sugary Drinks: What an 18-Month Randomized Trial Found
An 18-month randomized trial found that an interactive digital programme helped adults reduce sugary drinks...
Diabetes Technology in Primary Care: What a New ADA Scientific Statement Means for Patients
A new ADA scientific statement explains how CGM, connected insulin pens and automated insulin delivery...
Diabetes Apps in 2026: How to Choose Safer Tools
Diabetes apps can track glucose, food, medicines, and reports. Learn how to choose safer tools...
Diabetes and PCI: What the ILUMIEN IV Trial Found About OCT-Guided Stent Procedures
People with diabetes had higher two-year cardiovascular risk after PCI. Here is what the ILUMIEN...
Dexcom G7 Sensor Recall: Lot Numbers, Risks, and What to Do
Dexcom G7 sensor recall guide covering affected lots, stolen scrapped products, infection and no-reading risks...
CGM and Type 1 Diabetes Complications: What Adults Should Know
A nationwide Korean cohort study linked continuous glucose monitoring with lower rates of several serious...
Canagliflozin 100 mg vs 300 mg: What a New Kidney and Heart Outcomes Analysis Found
A post hoc CANVAS analysis found no clear kidney or cardiovascular advantage for canagliflozin 300...
Cagrilintide-semaglutide plus basal insulin lowered A1C and weight in adults with type 2 diabetes
A Lancet phase 3a trial found cagrilintide-semaglutide added to basal insulin lowered A1C and weight...
Berobenatide VESPER Results: What Patients Should Know
Phase 2b VESPER data suggest berobenatide may lower weight and A1C, but it remains investigational...